Technical Analysis for APLM - Apollomics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Inside Day | Range Contraction | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.08% | |
| Down 3 Days in a Row | Weakness | 0.08% | |
| Down 4 Days in a Row | Weakness | 0.08% | |
| Lower Bollinger Band Touch | Weakness | 0.08% | |
| Oversold Stochastic | Weakness | 0.08% | |
| Wide Bands | Range Expansion | -6.52% | |
| Down 3 Days in a Row | Weakness | -6.52% |
| Alert | Time |
|---|---|
| Down 3% | about 22 hours ago |
| Fell Below Lower Bollinger Band | about 22 hours ago |
| Down 2 % | about 22 hours ago |
| Down 1% | about 22 hours ago |
| Lower Bollinger Band Support | about 22 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/28/2024
Apollomics Inc. Description
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include investigating its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States, and developing an anti-cancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in Phase 1 and Phase 3 clinical trials in China.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Oncology Acute Myeloid Leukemia Chemotherapy Non Small Cell Lung Cancer Antineoplastic Drugs Leukemia Targeted Therapy Hematologic Cancers Oncology Therapies Treatment Of Non Small Cell Lung Cancer Phosphoinositide 3 Kinase Inhibitor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.79 |
| 52 Week Low | 0.1053 |
| Average Volume | 916,025 |
| 200-Day Moving Average | 0.36 |
| 50-Day Moving Average | 0.13 |
| 20-Day Moving Average | 0.13 |
| 10-Day Moving Average | 0.13 |
| Average True Range | 0.01 |
| RSI (14) | 37.11 |
| ADX | 13.35 |
| +DI | 17.17 |
| -DI | 26.70 |
| Chandelier Exit (Long, 3 ATRs) | 0.13 |
| Chandelier Exit (Short, 3 ATRs) | 0.15 |
| Upper Bollinger Bands | 0.15 |
| Lower Bollinger Band | 0.12 |
| Percent B (%b) | 0.08 |
| BandWidth | 25.23 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0017 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.13 | ||||
| Resistance 3 (R3) | 0.13 | 0.13 | 0.13 | ||
| Resistance 2 (R2) | 0.13 | 0.13 | 0.13 | 0.13 | |
| Resistance 1 (R1) | 0.12 | 0.12 | 0.13 | 0.12 | 0.13 |
| Pivot Point | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 |
| Support 1 (S1) | 0.11 | 0.12 | 0.12 | 0.11 | 0.11 |
| Support 2 (S2) | 0.11 | 0.11 | 0.11 | 0.11 | |
| Support 3 (S3) | 0.10 | 0.11 | 0.11 | ||
| Support 4 (S4) | 0.10 |
